5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Do O
not O
initiate O
STRIVERDI O
RESPIMAT O
in O
acutely O
deteriorating O
COPD O
patients O
( O
5.2 O
) O
* O
Do O
not O
use O
for O
relief O
of O
acute O
symptoms O
. O

Concomitant O
short-acting O
beta2-agonists O
can O
be O
used O
as O
needed O
for O
acute O
relief O
. O

( O
5.2 O
) O
* O
Do O
not O
exceed O
the O
recommended O
dose O
. O

Excessive O
use O
of O
STRIVERDI O
RESPIMAT O
, O
or O
use O
in O
conjunction O
with O
other O
medications O
containing O
LABA O
can O
result O
in O
clinically O
significant O
cardiovascular O
effects O
and O
may O
be O
fatal O
. O

( O
5.3 O
) O
* O
Life-threatening O
paradoxical O
bronchospasm O
can O
occur O
. O

Discontinue O
STRIVERDI O
RESPIMAT O
immediately O
. O

( O
5.4 O
) O
* O
Use O
with O
caution O
in O
patients O
with O
cardiovascular O
or O
convulsive O
disorders O
, O
thyrotoxicosis O
or O
sensitivity O
to O
sympathomimetic O
drugs O
( O
5.5 O
, O
5.6 O
) O
5.1 O
Asthma-Related O
Death O
[ O
see O
Boxed O
Warning O
] O
* O
Data O
from O
a O
large O
placebo-controlled O
study O
in O
asthma B-Not_AE_Candidate
patients O
showed O
that O
long-acting O
beta2-adrenergic O
agonists O
may O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

Data O
are O
not O
available O
to O
determine O
whether O
the O
rate O
of O
death B-NonOSE_AE
in O
patients O
with O
COPD B-Not_AE_Candidate
is O
increased O
by O
long-acting O
beta2-adrenergic O
agonists O
. O

* O
A O
28-week O
, O
placebo-controlled O
US O
study O
comparing O
the O
safety O
of O
another O
long-acting O
beta2-adrenergic O
agonist O
( O
salmeterol O
) O
with O
placebo O
, O
each O
added O
to O
usual O
asthma B-Not_AE_Candidate
therapy O
, O
showed O
an O
increase O
in O
asthma B-NonOSE_AE
-related O
deaths B-NonOSE_AE
in O
patients O
receiving O
salmeterol O
( O
13/13,176 O
in O
patients O
treated O
with O
salmeterol O
vs O
. O
3/13,179 O
in O
patients O
treated O
with O
placebo O
; O
RR O
4.37 O
, O
95 O
% O
CI O
1.25 O
, O
15.34 O
) O
. O

The O
increased O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
is O
considered O
a O
class O
effect O
of O
long-acting O
beta2-adrenergic O
agonists O
, O
including O
STRIVERDI O
RESPIMAT O
. O

No O
study O
adequate O
to O
determine O
whether O
the O
rate O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
is O
increased O
in O
patients O
treated O
with O
STRIVERDI O
RESPIMAT O
has O
been O
conducted O
. O

The O
safety O
and O
efficacy O
of O
STRIVERDI O
RESPIMAT O
in O
patients O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

STRIVERDI O
RESPIMAT O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.2 O
Deterioration O
of O
Disease O
and O
Acute O
Episodes O
STRIVERDI O
RESPIMAT O
should O
not O
be O
initiated O
in O
patients O
with O
acutely B-Not_AE_Candidate
deteriorating I-Not_AE_Candidate
COPD I-Not_AE_Candidate
, O
which O
may O
be O
a O
life-threatening O
condition O
. O

STRIVERDI O
RESPIMAT O
has O
not O
been O
studied O
in O
patients O
with O
acutely B-Not_AE_Candidate
deteriorating I-Not_AE_Candidate
COPD I-Not_AE_Candidate
. O

The O
use O
of O
STRIVERDI O
RESPIMAT O
in O
this O
setting O
is O
inappropriate O
. O

STRIVERDI O
RESPIMAT O
should O
not O
be O
used O
for O
the O
relief O
of O
acute O
symptoms O
, O
i.e. O
, O
as O
rescue O
therapy O
for O
the O
treatment O
of O
acute O
episodes O
of O
bronchospasm B-NonOSE_AE
. O

STRIVERDI O
RESPIMAT O
has O
not O
been O
studied O
in O
the O
relief O
of O
acute O
symptoms O
and O
extra O
doses O
should O
not O
be O
used O
for O
that O
purpose O
. O

Acute O
symptoms O
should O
be O
treated O
with O
an O
inhaled O
short-acting O
beta2-agonist O
. O

When O
beginning O
STRIVERDI O
RESPIMAT O
, O
patients O
who O
have O
been O
taking O
inhaled O
, O
short-acting O
beta2-agonists O
on O
a O
regular O
basis O
( O
e.g. O
, O
four O
times O
a O
day O
) O
should O
be O
instructed O
to O
discontinue O
the O
regular O
use O
of O
these O
drugs O
and O
use O
them O
only O
for O
symptomatic O
relief O
of O
acute O
respiratory B-NonOSE_AE
symptoms I-NonOSE_AE
. O

When O
prescribing O
STRIVERDI O
RESPIMAT O
, O
the O
healthcare O
provider O
should O
also O
prescribe O
an O
inhaled O
, O
short-acting O
beta2-agonist O
and O
instruct O
the O
patient O
on O
how O
it O
should O
be O
used O
. O

Increasing O
inhaled O
beta2-agonist O
use O
is O
a O
signal O
of O
deteriorating O
disease O
for O
which O
prompt O
medical O
attention O
is O
indicated O
. O

COPD B-Not_AE_Candidate
may O
deteriorate O
acutely O
over O
a O
period O
of O
hours O
or O
chronically O
over O
several O
days O
or O
longer O
. O

If O
STRIVERDI O
RESPIMAT O
no O
longer O
controls O
symptoms O
of O
bronchoconstriction B-NonOSE_AE
, O
or O
the O
patient O
's O
inhaled O
, O
short-acting O
beta2-agonist O
becomes O
less O
effective O
or O
the O
patient O
needs O
more O
inhalation O
of O
short-acting O
beta2-agonist O
than O
usual O
, O
these O
may O
be O
markers O
of O
deterioration O
of O
disease O
. O

In O
this O
setting O
, O
a O
re-evaluation O
of O
the O
patient O
and O
the O
COPD B-Not_AE_Candidate
treatment O
regimen O
should O
be O
undertaken O
at O
once O
. O

Increasing O
the O
daily O
dosage O
of O
STRIVERDI O
RESPIMAT O
beyond O
the O
recommended O
dose O
is O
not O
appropriate O
in O
this O
situation O
. O

5.3 O
Excessive O
Use O
of O
STRIVERDI O
RESPIMAT O
and O
Use O
with O
Long-Acting O
Beta2-Agonists O
As O
with O
other O
inhaled O
drugs O
containing O
beta2-adrenergic O
agents O
, O
STRIVERDI O
RESPIMAT O
should O
not O
be O
used O
more O
often O
than O
recommended O
, O
at O
higher O
doses O
than O
recommended O
, O
or O
in O
conjunction O
with O
other O
medications O
containing O
long-acting O
beta2-agonists O
, O
as O
an O
overdose B-NonOSE_AE
may O
result O
. O

Clinically O
significant O
cardiovascular B-NonOSE_AE
effects I-NonOSE_AE
and O
fatalities B-NonOSE_AE
have O
been O
reported O
in O
association O
with O
excessive O
use O
of O
inhaled O
sympathomimetic O
drugs O
. O

5.4 O
Paradoxical O
Bronchospasm O
As O
with O
other O
inhaled O
beta2-agonists O
, O
STRIVERDI O
RESPIMAT O
may O
produce O
paradoxical B-OSE_Labeled_AE
bronchospasm I-OSE_Labeled_AE
that O
may O
be O
life-threatening O
. O

If O
paradoxical B-NonOSE_AE
bronchospasm I-NonOSE_AE
occurs O
, O
STRIVERDI O
RESPIMAT O
should O
be O
discontinued O
immediately O
and O
alternative O
therapy O
instituted O
. O

5.5 O
Cardiovascular O
Effects O
STRIVERDI O
RESPIMAT O
, O
like O
other O
beta2-agonists O
, O
can O
produce O
a O
clinically O
significant O
cardiovascular B-OSE_Labeled_AE
effect I-OSE_Labeled_AE
in O
some O
patients O
as O
measured O
by O
increases B-OSE_Labeled_AE
in O
pulse O
rate O
, O
systolic I-OSE_Labeled_AE
or O
diastolic O
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
and/or O
symptoms O
. O

If O
such O
effects O
occur O
, O
STRIVERDI O
RESPIMAT O
may O
need O
to O
be O
discontinued O
. O

In O
addition O
, O
beta-agonists O
have O
been O
reported O
to O
produce O
ECG B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
such O
as O
flattening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
t I-OSE_Labeled_AE
he O
T O
wave I-OSE_Labeled_AE
, O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
, O
and O
ST B-OSE_Labeled_AE
segment I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
. O

The O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O

Long O
acting O
beta2-adrenergic O
agonists O
should O
be O
administered O
with O
caution O
in O
patients O
with O
cardiovascular B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
especially O
coronary B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
, O
cardiac B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
, O
hypertrophic B-Not_AE_Candidate
obstructive I-Not_AE_Candidate
cardiomyopathy I-Not_AE_Candidate
, O
and O
hypertension B-Not_AE_Candidate
. O

5.6 O
Co-existing O
Conditions O
STRIVERDI O
RESPIMAT O
, O
like O
other O
sympathomimetic O
amines O
, O
should O
be O
used O
with O
caution O
in O
patients O
with O
convulsive B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
thyrotoxicosis B-Not_AE_Candidate
, O
in O
patients O
with O
known O
or O
suspected O
prolongation B-Not_AE_Candidate
of O
the O
QT I-Not_AE_Candidate
interval I-Not_AE_Candidate
, O
and O
in O
patients O
who O
are O
unusually O
responsive O
to O
sympathomimetic O
amines O
. O

Doses O
of O
the O
related O
beta2-agonist O
albuterol O
, O
when O
administered O
intravenously O
, O
have O
been O
reported O
to O
aggravate B-NonOSE_AE
pre I-NonOSE_AE
- I-NonOSE_AE
existing I-NonOSE_AE
diabetes I-NonOSE_AE
mellitus I-NonOSE_AE
and O
ketoacidosis B-NonOSE_AE
. O

5.7 O
Hypokalemia O
and O
Hyperglycemia O
Beta-adrenergic O
agonists O
may O
produce O
significant O
hypokalemia B-OSE_Labeled_AE
in O
some O
patients O
, O
which O
has O
the O
potential O
to O
produce O
adverse O
cardiovascular B-NonOSE_AE
effects I-NonOSE_AE
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

The O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
is O
usually O
transient O
, O
not O
requiring O
supplementation O
. O

Inhalation O
of O
high O
doses O
of O
beta2-adrenergic O
agonists O
may O
produce O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
. O

In O
patients O
with O
severe O
COPD B-Not_AE_Candidate
, O
hypokalemia B-NonOSE_AE
may O
be O
potentiated O
by O
hypoxia B-Not_AE_Candidate
and O
concomitant O
treatment O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
, O
which O
may O
increase O
the O
susceptibility O
for O
cardiac B-NonOSE_AE
arrhythmias I-NonOSE_AE
. O

Clinically O
notable O
decreases B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
potassium I-NonOSE_AE
or O
changes B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
glucose I-NonOSE_AE
were O
infrequent O
during O
clinical O
studies O
with O
long-term O
administration O
of O
STRIVERDI O
RESPIMAT O
with O
the O
rates O
similar O
to O
those O
for O
placebo O
controls O
. O

STRIVERDI O
RESPIMAT O
has O
not O
been O
investigated O
in O
patients O
whose O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
is O
not O
well O
controlled O
. O

5.8 O
Hypersensitivity O
Reactions O
Immediate O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
angioedema B-OSE_Labeled_AE
, O
may O
occur O
after O
administration O
of O
STRIVERDI O
RESPIMAT O
. O

If O
such O
a O
reaction O
occurs O
, O
therapy O
with O
STRIVERDI O
RESPIMAT O
should O
be O
stopped O
at O
once O
and O
alternative O
treatment O
should O
be O
considered O
. O

